Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Simcere Pharmaceutical Co., Ltd.
Patients will be assessed for response after three cycles of treatment. Two additional cycles are recommended for CR, PR or SD patients, up to a maximum limit of six cycles in total. Patients will be followed up every three months until disease progression or death.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a diagnosis of CLL according to National Cancer Institute (NCI) Working Group criteria
No prior treatment for CLL
Binet stage B or C
ECOG performance status ≤ 2
Life expectancy ≥3 months
AST and ALT ≤ 3 x ULN; Total bilirubin ≤ 2 x ULN; Creatinine clearance ≥ 40 mL/min
Written informed consent
You may not be if
Patients were diagnosed with or treated for malignant tumors other than CLL (including central nervous system lymphoma) within one year prior to entering the study
Transformation to Richter's syndrome, or prolymphocytic leukemia (PLL)
Participation in any other clinical trials within 4 weeks prior to study entry
Any of the following conditions: severe heart failure; cardiomyopathy; myocardial infarction within 6 months; severe, uncontrolled diabetes; severe, uncontrolled hypertension; active, uncontrolled infection; central nervous system dysfunction
Patients received major surgery within 30 days prior to study entry